Several ex vivo analyses of CTLA-4 expression on CD4+ T cells, CD8+ T cells, monocytes, and PBMCs derived from treatment-naive MS patients and healthy counterparts did not reveal a significant difference between the two groups [109, 151, 152]. This evidence concerns the gene CD4 and myeloid sarcoma.